Suma Krishnan

Suma Krishnan (President, R&D) sold 25,000 shares for $7.7M via scheduled 10b5-1 plan on 2026-06-04

Suma Krishnan executed 11 separate sales totaling 25,000 shares for $7,702,825.22 on 2026-06-04 at a blended average price of $308.11, reducing his holdings from 1.40M to 1.38M shares (-1.8%). This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled execution rather than a discretionary trade. The sell occurred near KRYS's 52-week high of $319.48 (current price $301.00, down 5.8% from peak), and in the context of his same-ticker history at KRYS, prior sales in March 2026 showed modest 30-day returns (ranging -1.4% to +1.4%) but consistently positive 90-day outcomes (+10.8% to +14.0%). With KRYS trading at a 39.45 P/E and demonstrating strong fundamentals (annual revenue growth of +33.9%, latest quarter revenue of $116.4M and net income of $55.9M), the liquidation reflects execution of a pre-planned schedule rather than a signal about conviction in the company's trajectory.

President of R&D sold 25,000 shares at blended $263.21; stock now at $253.69, -13.1% from high

Krishnan Suma, President of R&D at Krystal Biotech, executed 10 separate sales totaling 25,000 shares for $6,580,270.42 on 2026-03-04, reducing holdings from 1,428,155 to 1,403,155 shares (-1.8%). The sales occurred at prices ranging from $257.32 to $266.42, with a blended average of $263.21, versus the current price of $253.69. The stock is currently -13.1% from its 52-week high of $291.93. At the same ticker, Suma's prior five trades (all sales on 2025-12-04) posted 90-day returns ranging from +19.5% to +23.7%; none were well-timed at the 90-day mark. His cross-ticker track record across 20 prior sales shows an average 90-day return of +21.8% with a 0.00% well-timed rate, indicating a consistent pattern of selling before price increases rather than declines. The company reports strong recent fundamentals: quarterly revenue of $97,800,000.00, net income of $79,365,000.00, annual revenue growth of +33.9%, and a P/E of 23.58.

KRYS President of R&D Krishnan Suma sells 50,000 shares for $11.0M via scheduled 10b5-1 plan adopted 2025-09-04

Krishnan Suma, President of R&D at Krystal Biotech, executed 16 separate sales totaling 50,000 shares for $11,007,332.86 at a blended average price of $220.15 on 2025-12-04. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning the sales were scheduled and not discretionary. The sales reduced his holdings from 1,528,056 shares to 1,478,056 shares, a reduction of 3.3% of pre-transaction holdings, leaving him with substantial remaining equity exposure. Since this sale was executed under a pre-established trading plan, it does not reflect real-time decision-making or a change in conviction; it represents a mechanical execution of a plan adopted approximately three months prior.

KRYS President of R&D Krishnan Suma sold 35,873 shares for $5,395,000.82 across 9 transactions via 10b5-1 plan

Krishnan Suma, President of R&D, executed 9 separate sales totaling 35,873 shares for $5,395,000.82 at a blended average price of $150.39 on 2025-07-14, 2025-07-15, and 2025-07-16. The filing is flagged as part of a pre-arranged 10b5-1 trading plan, meaning these are scheduled sales rather than discretionary transactions. Post-transaction holdings stand at 1,508,056 shares, representing a 2.3% reduction from pre-transaction holdings of 1,543,929 shares. Since the sales are governed by a 10b5-1 plan, this transaction reflects an established trading schedule rather than a discretionary response to market conditions or company-specific developments.

President of R&D Krishnan Suma sold 14,127 shares for $2.1M (6 sales on 2025-07-09/10) under 10b5-1 plan.

Krishnan Suma, President of R&D at Krystal Biotech, executed 6 separate sales totaling 14,127 shares for $2,122,834.96 at a blended average price of $150.27 across July 9–10, 2025. The transaction represents a 0.9% reduction in his holdings, leaving 1,525,929 shares post-trade. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2024-09-12, meaning the sales were scheduled rather than discretionary. For a major R&D executive, a modest portfolio reduction under a pre-existing plan does not signal material conviction shifts, but the continued substantial shareholding of 1.53M shares indicates ongoing material investment in the company.

KRYS President of R&D Krishnan Suma sold 50,000 shares for $8.9M at blended average $177.79 on 2025-03-13

Krishnan Suma, President of R&D at Krystal Biotech, executed 10 separate sales totaling 50,000 shares for $8,889,524.57 on 2025-03-13, reducing his holdings from 1,583,056 to 1,533,056 shares (a 3.2% reduction). The transaction occurred at prices ranging from $175.83 to $179.57, with a blended average of $177.79, slightly above the current price of $177.37. The company shows strong recent momentum (+18.3% over 30 days) and robust fundamentals (annual revenue growth of +473.0%, net income of $27,180,000.00). Notably, across Suma's prior 5 sales at KRYS in December 2024, none were well-timed at the 90-day horizon—all resulted in positive average returns, meaning the stock rose after each sale. Given the substantial position retained (1,533,056 shares post-transaction), the timing relative to the company's strong growth trajectory and recent positive price momentum warrants observation.

KRYS President, R&D Krishnan Suma sold 50,000 shares for $8.2M on 2024-12-13 via pre-arranged 10b5-1 plan

Krishnan Suma executed 17 separate sales totaling 50,000 shares for $8,240,023.06, with prices ranging from $163.04 to $171.63 across the single trading day. The transaction reduces his holdings from 1.59M shares to 1.54M shares (-3.2% of pre-transaction position). This activity was conducted under a pre-arranged 10b5-1 trading plan adopted on 2024-06-13, meaning the sales were scheduled and not discretionary. Investors should note that as a scheduled divestment under a pre-established plan, this sale reflects a predetermined trading schedule rather than a real-time decision based on current market conditions or company fundamentals.

Krishnan Suma (Pres, R&D) sold 50,000 shares at avg $197.77 for $9.9M on 2024-09-12

Krishnan Suma executed 15 separate sales totaling 50,000 shares for $9,888,276.35 at blended average price $197.77, reducing his holdings from 1,612,262 to 1,562,262 shares (-3.1%). The sale occurred as the stock traded near 52-week highs (current $201.58, within 5.6% of $213.66 range peak) and follows strong near-term momentum (+7.0% 30-day, +13.4% 90-day). His prior five trades at KRYS (all on 2024-06-11) posted positive 90-day returns ranging from 5.2% to 9.4%, with 0 of 5 being well-timed sells (stock rose after each); his cross-ticker track record shows 20 prior sells with 20.00% well-timed rate and modest average post-sell returns (+11.4% 30-day, +5.2% 90-day). The company trades at a P/E of 54.63 on $70.3M quarterly revenue and $15.6M net income. Without visibility into scheduling (10b5-1 plan disclosure) or other context, the timing against elevated valuation multiples warrants monitoring.